Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cutting Waste in Bronchoscopy: A Multicenter Observational Study in the German Health Care System.

Chest·2026
Same author

Thoracic impedance pneumography in propofol-sedated patients undergoing percutaneous endoscopic gastrostomy (PEG) placement in gastrointestinal endoscopy: A prospective, randomized trial.

Journal of clinical anesthesia·2024
Same author

Computed Tomography Radiomics to Differentiate Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same author

[Strategietreffen: Virushepatitis in Deutschland eliminieren].

Zeitschrift fur Gastroenterologie·2023
Same author

Zeitschrift fur Gastroenterologie·2020
Same author

Individual invitation letters lead to significant increase in attendance for screening colonoscopies: Results of a pilot study in Northern Hesse, Germany.

United European gastroenterology journal·2018

Related Experiment Video

Updated: May 26, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

New developments in HCV therapy.

B Kronenberger1, S Zeuzem

  • 1Department of Internal Medicine 1, Hospital of the Johann Wolfgang Goethe-University, Frankfurt am Main, Germany.

Journal of Viral Hepatitis
|January 12, 2012
PubMed
Summary
This summary is machine-generated.

New direct antiviral drugs show promise for treating chronic hepatitis C, improving cure rates when combined with standard therapy. Future research aims to enhance tolerability and overcome viral resistance.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Related Experiment Videos

Last Updated: May 26, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis C remains a significant health concern, with current peginterferon α/ribavirin therapy failing to cure approximately half of patients.
  • Direct-acting antiviral (DAA) agents targeting viral proteins offer a potential alternative to standard therapy.
  • Key targets for DAAs include the NS3/4A protease, NS5B polymerase, and NS5A protein.

Purpose of the Study:

  • To evaluate the efficacy and safety of novel direct antiviral drugs for chronic hepatitis C treatment.
  • To assess the potential of DAAs to overcome limitations of existing therapies, including resistance and tolerability issues.
  • To explore combination therapies involving DAAs, with or without interferon α/ribavirin.

Main Methods:

  • Clinical trials evaluating direct antiviral agents targeting NS3/4A protease, NS5B polymerase, and NS5A.
  • Phase III trials (SPRINT-2 and ADVANCE) assessed NS3/4A protease inhibitors (boceprevir and telaprevir) in combination with standard care.
  • Studies investigating combinations of different novel DAAs and interferon-based regimens.

Main Results:

  • Phase III trials demonstrated that combining boceprevir or telaprevir with standard care significantly increased sustained virologic response rates in treatment-naïve genotype 1 patients (from 38-44% to 66-75%).
  • Early trials highlighted the potential for rapid selection of resistant Hepatitis C virus variants.
  • Some DAA development was halted due to safety and tolerability concerns.

Conclusions:

  • Direct antiviral agents, particularly NS3/4A protease inhibitors, have shown significant potential to improve treatment outcomes for chronic hepatitis C.
  • Future therapeutic goals include enhancing drug tolerability, shortening treatment duration, and developing strategies to manage viral resistance.
  • Combination therapies with novel DAAs represent the future direction for hepatitis C treatment.